ecancermedicalscience

Research

Clinicopathologic features of endometrial cancer with mismatch repair deficiency

18 Jun 2020
Sushmita Gordhandas, Ryan M Kahn, Charlotte Gamble, Nizam Talukdar, Brandon Maddy, Becky Baltich Nelson, Gulce Askin, Paul J Christos, Kevin Holcomb, Thomas A Caputo, Eloise Chapman-Davis, Melissa K Frey

The inclusion of DNA mismatch repair (MMR) evaluation as a standard of care for endometrial cancer management will result in a growing population of patients with MMR deficiency and negative germline Lynch syndrome testing (MMR-deficient). In this systematic review and study, the clinicopathologic features of endometrial cancer in patients with MMR-intact, MLH1 methylation positive, MMR-deficient or Lynch syndrome are evaluated. A systematic search of online databases between 1990 and 2018 identified studies of endometrial cancer patients with tumour testing (MMR protein immunohistochemistry or microsatellite instability) and germline assessment for Lynch syndrome. Extracted data included tumour testing, germline genetic testing, age, body mass index (BMI), family history, tumour stage, grade and histologic type. Associations between MMR-intact, MLH1 methylation positive, MMR-deficient and Lynch syndrome groups were analysed using descriptive statistics. The comprehensive search produced 4,400 publications, 29 met inclusion criteria. A total of 7,057 endometrial cancer cases were identified, 1,612 with abnormal immunohistochemistry, 977 with microsatellite instability. Nine-hundred patients underwent germline genetic testing, identifying 212 patients with Lynch syndrome. Patients in the Lynch syndrome and MMR-deficient groups were significantly younger than patients in the MMR-intact and MLH1 methylation positive groups. Patients with MMR-intact tumours had the highest BMI, followed by MMR-deficient, then Lynch syndrome. MMR-intact tumours were more likely to be grade I at diagnosis than other groups. Patients with Lynch syndrome and MMR-deficient tumours were less likely to have stage I disease as compared to patients with MMR-intact tumours. Endometrial cancer patients with MMR-deficient tumours have similar features to those with germline Lynch syndrome mutations, including age, grade, histology and stage. Even in the absence of a germline mutation, tumour evaluation for MMR status may have important clinical implications.

Related Articles

Nikhil Bathija, Rohit Mahajan, Anil Kumar Goel, Siva Ranjani, Mounika Sirimalla, Gourav Kaushal, Sapna Marcus, Shilpa Jain, Madhur Verma, Deep Shikha, Korukonda Vinod Kumar, Jyoti Sharma
Pavan Raju Kola, Amith Paruchuri, Nimisha Preman, Hemavathi Baskarane, Vishakha Hooda, Aparna Sharma, Ishaan Gupta, Saran Kumar, Shilpi Minocha, Pranay Tanwar, Mohit Kumar Divakar, Atul Batra
Loreto Fernández-González, Rodrigo Lagos, Piero Bettoli, Loreto Moreira, Jaime Sapag, David Kissane
Pallavi Rajput, Vandita Pahwa, Charu Singh, Sankalp Sancheti, Ravikiran Pawar, Shikha Jain, Gurwinder Kaur, Kundan Rao, Navin Bansal, Rahat Brar, Tapas Dora, Ashish Gulia
Edwin Saji, Jason Jacob, Udaya Kumar Damodaran, Sabah Kulsum, Sharanya Tripathi, Akshat Saxena, Panah Parab, Utkarsh Dayal, Priyal Dilip Mehta, Aju Mathew